What is William Blair's Estimate for DNTH Q1 Earnings?

Key Points

• William Blair predicts that Dianthus Therapeutics will report a Q1 2026 earnings loss of ($0.75) per share, maintaining an "Outperform" rating on the stock.
• The company recently reported its earnings results, showing a loss of ($0.88) per share, which was worse than the consensus estimate of ($0.86) per share.
• Dianthus Therapeutics is currently valued at approximately $603.32 million, with a recent stock price of $18.76 and an average price target of $53.00.

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) - Research analysts at William Blair issued their Q1 2026 earnings per share estimates for Dianthus Therapeutics in a report issued on Thursday, August 7th. William Blair analyst M. Minter expects that the company will earn ($0.75) per share for the quarter. William Blair has a "Outperform" rating on the stock. The consensus estimate for Dianthus Therapeutics' current full-year earnings is ($2.61) per share. William Blair also issued estimates for Dianthus Therapeutics' Q2 2026 earnings at ($0.78) EPS and Q3 2026 earnings at ($0.80) EPS.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.86) by ($0.02). The business had revenue of $0.19 million during the quarter, compared to analyst estimates of $0.87 million. Dianthus Therapeutics had a negative net margin of 2,364.56% and a negative return on equity of 33.78%.

DNTH has been the subject of several other reports. Robert W. Baird decreased their price objective on Dianthus Therapeutics from $58.00 to $50.00 and set an "outperform" rating for the company in a report on Tuesday, May 13th. HC Wainwright reissued a "buy" rating and issued a $40.00 price objective on shares of Dianthus Therapeutics in a report on Tuesday, May 13th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $53.00.

Dianthus Therapeutics Trading Down 2.0%

DNTH stock opened at $18.76 on Monday. The company has a market capitalization of $603.32 million, a P/E ratio of -5.77 and a beta of 1.43. Dianthus Therapeutics has a twelve month low of $13.36 and a twelve month high of $32.27. The business has a 50 day simple moving average of $19.29 and a 200-day simple moving average of $20.02.

Institutional Investors Weigh In On Dianthus Therapeutics

Several large investors have recently modified their holdings of DNTH. KLP Kapitalforvaltning AS purchased a new stake in shares of Dianthus Therapeutics during the fourth quarter worth approximately $33,000. JPMorgan Chase & Co. boosted its stake in shares of Dianthus Therapeutics by 14.0% during the fourth quarter. JPMorgan Chase & Co. now owns 12,129 shares of the company's stock valued at $264,000 after acquiring an additional 1,490 shares during the last quarter. Wellington Management Group LLP boosted its stake in shares of Dianthus Therapeutics by 12.2% during the fourth quarter. Wellington Management Group LLP now owns 60,337 shares of the company's stock valued at $1,315,000 after acquiring an additional 6,552 shares during the last quarter. FMR LLC boosted its stake in shares of Dianthus Therapeutics by 0.8% during the fourth quarter. FMR LLC now owns 4,439,281 shares of the company's stock valued at $96,776,000 after acquiring an additional 36,133 shares during the last quarter. Finally, Invesco Ltd. boosted its stake in shares of Dianthus Therapeutics by 7.4% during the fourth quarter. Invesco Ltd. now owns 11,521 shares of the company's stock valued at $251,000 after acquiring an additional 790 shares during the last quarter. Hedge funds and other institutional investors own 47.53% of the company's stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.